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ABSTRACT
Objective: To calculate sustainable generic prices for
4 tyrosine kinase inhibitors (TKIs).
Background: TKIs have proven survival benefits in the
treatment of several cancers, including chronic myeloid
leukaemia, breast, liver, renal and lung cancer.
However, current high prices are a barrier to treatment.
Mass production of low-cost generic antiretrovirals has
led to over 13 million people being on HIV/AIDS
treatment worldwide. This analysis estimates target
prices for generic TKIs, assuming similar methods of
mass production.
Methods: Four TKIs with patent expiry dates in the
next 5 years were selected for analysis: imatinib,
erlotinib, lapatinib and sorafenib. Chemistry, dosing,
published data on per-kilogram pricing for commercial
transactions of active pharmaceutical ingredient (API),
and quotes from manufacturers were used to estimate
costs of production. Analysis included costs of
excipients, formulation, packaging, shipping and a
50% profit margin. Target prices were compared with
current prices. Global numbers of patients eligible for
treatment with each TKI were estimated.
Results: API costs per kg were $347–$746 for
imatinib, $2470 for erlotinib, $4671 for lapatinib, and
$3000 for sorafenib. Basing on annual dose
requirements, costs of formulation/packaging and a
50% profit margin, target generic prices per person-
year were $128–$216 for imatinib, $240 for erlotinib,
$1450 for sorafenib, and $4020 for lapatinib. Over 1
million people would be newly eligible to start
treatment with these TKIs annually.
Conclusions: Mass generic production of several
TKIs could achieve treatment prices in the range of
$128–$4020 per person-year, versus current US prices
of $75161–$139 138. Generic TKIs could allow
significant savings and scaling-up of treatment
globally, for over 1 million eligible patients.
INTRODUCTION
Worldwide, there were 8.2 million deaths due
to cancer in 2012,1 and incidence is
expected to rise by 70% over the next
20 years.2 The majority of cancer cases and
deaths occur in Africa, Asia, Central and
South America.2 Fatality rates are much
higher in low-income and middle-income
countries (LMICs). For all cancers, the case
fatality rate is 74.5% in low-income countries,
compared to 46.3% in high-income
countries.3
Tyrosine kinase inhibitors (TKIs) target
tumour cells by interfering with signalling
pathways that are involved in cell growth and
division.4 Imatinib mesylate is licensed as
ﬁrst-line treatment for adults with chronic-
phase Philadelphia-chromosome-positive
(Ph+) chronic myeloid leukaemia (CML),
and for the management of gastrointestinal
stromal tumours (GIST), and as salvage
therapy for Ph+ acute lymphoblastic lymph-
oma.5 Erlotinib is licensed as a ﬁrst-line treat-
ment of locally advanced or metastatic
non-small cell lung cancer (NSCLC) with
activating epidermal growth factor receptor
mutations.6 Sorafenib is licensed as a second-
Strengths and limitations of this study
▪ This study calculated estimated generic prices
for four tyrosine kinase inhibitors using an algo-
rithm based on publicly available data on com-
pleted sales of the pharmaceutical ingredients.
▪ Publicly available data were used to calculate the
global number of people eligible for treatment,
as well as to present a global price overview, for
each medicine.
▪ The estimation methods are limited by the
assumption of absence of intellectual property
and other trade barriers, and the assumption of
robust demand volume and market competition
for these medicines.
▪ The methods used to estimate the global
number eligible for treatment with the medicines
are limited by sparse data on cancer subtype epi-
demiology—the effect is likely to be one of
underestimation.
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line treatment for renal cell carcinoma (RCC) and unre-
sectable hepatocellular carcinoma (HCC).7 Lapatinib is
licensed for advanced HER2-positive breast cancer.8
There were no TKIs in WHO’s Model List of Essential
Medicines (EML) until the recently published 19th
edition, in which the only TKI is imatinib,9 10 despite
strong evidence for the efﬁcacy of other TKIs. NGOs
have highlighted that the high prices of medicines pose
a potential obstacle to their inclusion,11 as comparative
cost-effectiveness is a criterion for addition to the WHO
EML.12 The low number of TKIs on the WHO EML is
reﬂected in national Essential Medicines Lists. Over 75%
of national EMLs in all regions except Europe do not
include any tyrosine kinase inhibitors, and in nearly all
LMICs, public procurement is based on national
EMLs.13 It has been estimated that only 15% of patients
in LMICs in Southeast Asia have access to an index of
cancer medicines, including erlotinib and sorafenib.14
High prices act as a barrier to access also in high-income
countries. For example, in the UK, sorafenib is not avail-
able in the NHS due to insufﬁcient cost-effectiveness.15
The impact of this lack of access on patients has been
widely documented.16–18 The high prices of leukaemia
drugs have been strongly criticised by a large group of
experts, who have suggested they conﬂict with fulﬁlling
the Hippocratic Oath.19
The price-reducing effect of generic competition can
transform how diseases are treated. In the ﬁeld of HIV/
AIDS medicines, generic competition was encouraged
by resource allocation for their purchase and the use of
ﬂexibilities in trade law allowing the importation of gen-
erics where normally importation would have been pre-
vented by patent protection. The 99% reduction in the
prices of antiretrovirals following generic competition,
from $10 000 per person per year down to $100 has
been a key factor in the expansion of antiretroviral treat-
ment to over 13 million people in 2014.20 21 Similar ana-
lyses of minimum prices have been performed for
hepatitis C drugs,22 and for the hepatitis B treatment
entecavir.23 This paper estimates target prices for
generic TKIs that could be achieved when their patent
terms expire within the next 5 years, or when patents no
longer form a barrier to generic entry otherwise—for
example by licensing to generic manufacturers.
METHODS
We focus on four TKIs with anticipated patent expiry
dates within the next 5 years. The chemical structures
and excipient contents for all TKIs were gathered from
prescribing information published by the originator
companies (see online supplementary appendix 1). For
each TKI, chemical structures, dosing and published
data on per-kilogram pricing for the active pharmaceut-
ical ingredient (API) were reviewed. Analysis included
costs of excipients, formulation, packaging, shipping
and a 50% proﬁt margin. Results were validated by inde-
pendent estimates from a single large generic company.
Calculation of treatment cost
We derived target prices using an algorithm based on
per-kilogram prices of the APIs, previously used in ana-
lyses of drugs for hepatitis C and B.22 23 Current manu-
facturers of API were contacted to request quotes for
price per kilogram, and export data for India were
reviewed for 2014 and early 2015 to estimate a reason-
able lower price for the APIs.24
Calculations for all TKIs analysed are shown in table 1,
and the target price calculation for erlotinib is displayed
as a ﬂowchart in ﬁgure 1 as an example of the algorithm
used. The dose of erlotinib is 150 mg once daily, so
1 year’s supply of the drug would require 55 g of the
API. One kilogram of erlotinib API was estimated to cost
$2470. Annual dosing regimens were combined with API
prices to yield the per-tablet cost of API ($0.37). We
added conservative estimates for the costs of excipients
and tableting and multiply by 30 to yield monthly cost of
production ($11.90/month). The prices of excipients
were incorporated into the target price by assuming that
all of the non-API mass of the tablet is made up of the
most expensive excipient, and that the total weight of
the tablet is ﬁve times the weight of API alone. To this
Table 1 Assumptions and calculations of target prices
Medicine Imatinib Erlotinib Sorafenib Lapatinib
API per tablet 400 mg 150 mg 200 mg 250 mg
Tablets per month 28 28 112 168
API price per kilogram $347–$746 $2470 $3000 $4671
API cost per tablet $0.14–$0.30 $0.37 $0.60 $1.17
Add cost of excipients and formulation $0.18–$0.34 $0.38 $0.62 $1.18
Add cost of tableting $0.22–$0.38 $0.42 $0.66 $1.22
Cost per month $6.22–$10.68 $11.90 $73.83 $205.26
Add cost of bottle, packaging, shipping, duties $6.57–$11.03 $12.25 $74.18 $205.61
Add 50% mark-up $9.85–$16.55 $18.37 $111.27 $308.41
Target price per year $128–$216 $240 $1450 $4020
The prices of excipients used for each TKI are given in text, but not shown in table.
API, active pharmaceutical ingredient; TKI, tyrosine kinase inhibitor.
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cost estimate, we added costs of shipping and duties at
$0.35/month, assuming one bottle delivered to the
patient every month ($12.25/month). Costs estimated
for these components are conservative and would repre-
sent a relatively inefﬁcient manufacturing process. Last,
we added a 50% mark-up to this cost of production to
estimate a target price that would be proﬁtable and sus-
tainable, to encourage market entry and competition
among generic producers ($18.37/month). We divided
this price by 28 and multiplied by 365 to give a target
price per patient-year ($240/year).
Patent coverage and global prices
Estimated patent expiry dates for the USA and EU were
gathered from originator company reports (see online
supplementary appendix 2). The patent statuses of the
TKIs in India were reviewed.
Prices for the chosen TKIs were identiﬁed in 12 coun-
tries, using national databases and online price compari-
son tools (see online supplementary appendix 3). In all
cases, the lowest available price per pill was used for
comparison. Where pricing information for a medicine
was not found for a country, no bar is displayed.
Incidence of cancers and volume demand
Using published ﬁgures of the epidemiology of cancers
for which the chosen TKIs are indicated, we conserva-
tively estimated annual volume of demand, in terms of
the number of people newly eligible for treatment per
year. We estimated the incidence of all cancers treated
with the TKIs analysed, including renal cell carcinoma,
hepatocellular carcinoma, thyroid carcinoma, chronic
myeloid leukaemia, acute lymphoblastic leukaemia, pan-
creatic cancer, non-small cell lung cancer and breast
cancer. The annual number eligible is multiplied by the
annual requirement of API in grams, per patient, to give
annual volume demand. Our assumptions and estimates
are presented in table 2, and references used are given
in online supplementary appendix 4.
Figure 1 Cost estimation flow chart for erlotinib. API, active
pharmaceutical ingredient.
Table 2 Indications, dosing, originator company and patent expiry dates for selected TKIs
Medicine Indication(s)* Dose(s)*
Originator
company
Expiry of
term for
base
compound
patent† Target price per
patient per yearUSA EU
Imatinib
(Glivec/Gleevec)
Chronic myeloid leukaemia 400 mg QD Novartis 2015 2016 $128–$216
Erlotinib (Tarceva) Non-small cell lung cancer
(locally advanced or metastatic)
150 mg QD Roche 2018 2020 $240
Sorafenib (Nexavar) Renal cell carcinoma,
Hepatocellular carcinoma
400 mg BID Bayer and Onyx
Pharmaceuticals
2020 2020 $1450
Lapatinib
(Tyverb/Tykerb)
Advanced breast cancer 1500 mg QD Novartis 2020 2023 $4020
*References in online supplementary appendix 1.
†References for patent expiry dates are given in online supplementary appendix 2 and assume no supplementary patent term extensions.
BID, two times a day; QD, daily; TKI, tyrosine kinase inhibitor.
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Incidence data for International Classiﬁcation of
Diseases (ICD) 10 categories was obtained from
Globocan 2012,1 and incidence of speciﬁc cancer types
was estimated from these ﬁgures using data from other
studies on the proportion of cases of the cancer
subtype within the ICD10 group. For example, renal
cell carcinoma is included in the ICD10 category
‘kidney cancer’, and represents 85% of incidence in
this category. In breast cancer, data was only available
for female incidence.
In our estimates of the number globally eligible for
treatment, we included published data on the propor-
tion of cases that are receptor/chromosome positive,
relapsed/refractory to treatment, and advanced/meta-
static at presentation. Owing to the lack of similar data
for LMICs, these estimates are largely based on data
from high-income countries (HICs); where ﬁgures were
available for both, these ﬁgures were combined to esti-
mate global incidence.
Our estimates assumed full access to all interventions
indicated before use of TKIs, including surgery, radio-
therapy and chemotherapy. We do not include mea-
sures of access in our assumptions; where patients do
not have access to these interventions, TKIs may
provide the best available treatment due to low cost,
potentially increasing the eligible population. In add-
ition, data from HICs for the proportion of cases that
are advanced/metastatic at presentation is likely to
underestimate the proportion in countries with
reduced access to healthcare services and health infor-
mation. Our estimates of the global eligible population
are thus conservative.
RESULTS
Chemical descriptions and calculated target prices
The chemical structures of the TKIs are shown in
ﬁgure 2. Calculations of treatment cost are shown in
table 1. The price of API for imatinib, erlotinib and
lapatinib have been estimated primarily using data on
exports from India,24 while the API price for sorafenib
was obtained by personal communication with a large
generic manufacturer.
Imatinib
The standard dose for imatinib is 400 mg daily, equiva-
lent to an API requirement of 146 g per person-year.
Prices of exported imatinib have decreased dramatically
over the last 5 years, as multiple generic manufacturers
compete, and as manufacturing processes are optimised
(data not shown). Nevertheless, a wider distribution of
stable prices is seen in imatinib API than for the other
drugs. For imatinib, we therefore present a range of esti-
mated target prices.
There is already a signiﬁcant demand in volume for
imatinib. There are multiple suppliers of API, and there
are alternative processes for which patent applications
have been ﬁled. API is sold at a wide range of prices to
different markets: distinct markets for the API exist, for
which the pricing may be as low as $340/kg. In 2014,
68 kg of imatinib API were shipped for $340–$347/kg. A
market of $340–$1000/kg exists for Argentina, Ecuador,
Bangladesh, Singapore, Mexico and the USA; this
market represents an approximate total volume of
750 kg of API exported from India in 2014 in 15 ship-
ments. In medium-tiered pricing markets, we see a
range of $1000–$2000/kg for the API including coun-
tries UAE, Jordan and Bangladesh, representing an
approximate export volume of 840 kg of API in the last
year from India. In high-tiered pricing markets, API is
exported from India to the UAE, Israel, Canada, Iran
and the USA, with a price range of $2000–$5000/kg,
Figure 2 Chemical structures, formulae and molecular
weights.
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Table 3 Global incidence of indicated cancers, and estimates of total numbers eligible for treatment with selected TKIs
TKI and
standard dose
ICD10
category and
incidence
Indication of TKI,
and percentage of
relevant ICD10
group
Eligibility in terms of
pathology, and
percentage of incident
cases with this subtype
Eligibility in terms
of stage of disease,
a percentage of
incident cases at
this stage
Total number
newly eligible
for indication,
per year
Total
number
newly
eligible for
TKI, per
year
Total API
requirement per
year, in tonnes, to
meet incident
demand
Imatinib 400 mg
QD
Leukaemia
(C91–95),
351 965
Chronic myeloid
leukaemia, 12.3%
Philadelphia chromosome
positive, 87.5%
NA, 100% 37 880 47 999 7.0
Leukaemia
(C91–95),
351 965
Acute lymphoblastic
leukaemia, 11.5%
Philadelphia chromosome
positive, 25%
NA, 100% 10 119
Erlotinib 150 mg
QD for NSCLC,
100 mg QD for
pancreatic
cancer
Trachea,
bronchus and
lung (C33–34),
1 824 701
Non-small cell lung
cancer, 85%
Proportion of patients for
whom EGFR status can
be evaluated and are
EGFR positive, 14.6%
Advanced/metastatic,
83.5%
189 082 442 486 19.6
Pancreatic
cancer,
337 872
Pancreatic cancer,
100%
All, 100% Advanced/metastatic,
75%
253 404
Sorafenib
400 mg BID
Kidney cancer,
337 860
Renal cell
carcinoma, 85%
All, 100% Advanced/metastatic,
71.5%
205 334 443 734 129.6
Liver cancer,
782 451
Hepatocellular
carcinoma, 87.5%
All, 100% Advanced/metastatic,
30%
205 393
Thyroid cancer,
298 102
Thyroid carcinoma,
95%
Iodine-refractory, 66.6% Advanced/metastatic,
17.5%
33 007
Lapatinib
1500 mg QD
Breast cancer,
1 671 149
Breast cancer,
100%
HER-2 positive, 12.5% Advanced/metastatic,
33.5%
69 979 69 979 38.3
Gastrointestinal stromal tumour, for which imatinib and sunitinib are indicated treatments in some cases, has not been included, due to its relative rarity, and the fact that it spans multiple
ICD10 categories. References for figures used in this table can be found in online supplementary appendix 4.
API, active pharmaceutical ingredient; BID, two times a day; EGFR, epidermal growth factor receptor; ICD, International Classification of Diseases; NA, not applicable; NSCLC, non-small cell
lung cancer; QD, daily; TKI, tyrosine kinase inhibitor.
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and an approximate volume of 4.5 tonnes in the last
year from India.
We have estimated a range of target prices based on
the robust low-tier market, using an API price of $347/
kg for the lower estimate, and $746/kg for the higher
estimate (weighted average within the $340–$1000/kg
market). The most expensive excipient in imatinib mesy-
late is crospovidone (median price $27/kg). This yields
a per-year target price of $128–$216.
Erlotinib
The standard dose for erlotinib is 150 mg daily, equiva-
lent to an API requirement of 55 g per patient per year.
Erlotinib API exports from India showed a lowest price
of $2470/kg in 2014. The most expensive excipient used
is hypromellose (median price $24/kg). This yields a
per-year target price of $240.
Sorafenib
The standard dose for sorafenib is 400 mg twice daily,
equivalent to an API requirement of 292 g per patient
per year. Sorafenib API exports from India showed a
lowest price of $7472 per kilogram in 2014, with a low
volume of total shipments. However, we received a quote
of $3000/kg from a large Indian generics company,
which we used for our target price estimate. The most
expensive excipient used is hypromellose (median price
$24/kg). This yields a per-year target price of $1450.
Lapatinib
The standard dose for lapatinib is 1500 mg once daily,
equivalent to an API requirement of 548 g per patient
per year. Lapatinib API was exported from India twice in
2014, with a mean price of $4674/kg. The most expen-
sive excipient used in lapatinib ditosylate is povidone
Figure 3 Lowest available prices in selected countries. Lowest available price for (A) imatinib (400 mg) (sources in online
supplementary appendix 3); (B) erlotinib (150 mg) (sources in online supplementary appendix 3); (C) sorafenib (400 mg two
times a day) (sources in online supplementary appendix 3); and (D) lapatinib (1500 mg) (sources in online supplementary
appendix 3) in selected countries.
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(median price $14/kg). This yields a per-year target
price of $4020.
Patent expiry
Expiry dates of patent protection for the TKIs surveyed
are presented in table 2 and references are given in
online supplementary appendix 2. Basic patent protec-
tion for imatinib mesylate will expire in 2015 (USA) and
2016 (EU). For erlotinib—2018 (USA) and 2020 (EU).
For sorafenib—in 2020 (USA and EU). For lapatinib—in
2020 (USA) and 2023 (EU).
Imatinib and sorafenib are not under patent protec-
tion in India. Lapatinib is under patent protection in
India until 2019, and patent protection for erlotinib is
the subject of an ongoing court case between Roche
and Cipla (see online supplementary appendix 2).
Generic erlotinib manufactured by Teva Canada has
recently been approved for sale in Canada.25 While
these basic patents expire in the next 5 years, secondary
patents granted on the use of these compounds in com-
bination treatments may pose barriers to generic market
entry.
Global demand
Global demand estimates based on incidence and eligi-
bility are presented in table 3. Erlotinib, sorafenib and
lapatinib have considerable volume demand, where even
conservative estimates of proportion treated (eg, 30% of
eligible population) would yield demands sufﬁcient for
sustainable competitive manufacture. For imatinib, esti-
mated volume demands are lower, although still compar-
able in numbers to, for example, those receiving
paediatric second-line HIV treatment.21 In the case of
imatinib, robust competition is already demonstrated in
large export volumes and price reductions seen over the
past 5 years.
Current prices
Figure 3A–D illustrates the ranges across countries in
prices for each of the four TKIs analysed. Data sources
for these prices are given in online supplementary
appendix 3. Indian generic prices (when available) were
always found to be signiﬁcantly lower than all other
prices. US prices were, in most cases, at least twice as
high as those in EU. There was little variation between
brand prices for France, the UK, Spain and, in general,
Thai, Brazilian, Russian and South African prices were
lower than those of the European countries, with the
notable exceptions of sorafenib in Thailand. The lowest
price in ﬁgure 3C is offered by Cipla, and this is below
our target price.26
Generic imatinib was available in Canada, Latvia,
South Africa, Brazil and India, but not other countries
surveyed. Generic erlotinib and sorafenib versions were
available in India but not other countries surveyed.
Generic versions of lapatinib were not available in any of
the countries surveyed.
DISCUSSION
If produced generically with adequate competition, imati-
nib, erlotinib, lapatinib and sorafenib can be made avail-
able at low prices, making their use feasible in developing
countries, and allowing large savings in high-income
countries. We demonstrate that generic versions of imati-
nib can be sustainably and proﬁtably produced at a price
between $128 and $216 per person-year, which are far
lower than the current prices of around $30 000 in EU
and $107 799 per person-year in the USA. Generic erloti-
nib could be produced for $240 per person-year, versus
the current EU prices of $26 416–$36 678, and US price
of $79 891. Generic versions of lapatinib and sorafenib
can be sustainably produced at 1–11% of the current
prices in high-income countries. At the target prices
identiﬁed, $1 billion would be enough to treat all 1
million patients worldwide who become eligible for treat-
ment with imatinib, erlotinib, sorafenib and lapatinib,
every year. This combined cost is less than a quarter of
the net sales of $4.7 billion for imatinib in 2013 alone.27
The estimates presented in this paper are based on
actual, completed sales of API. We assume an inefﬁcient
manufacturing process and include all real-world
expenses, such as packaging, shipping and duties.
Limitations of our analysis include the potential delaying
effect of secondary patents. All four drugs analysed are
under multiple secondary patents, but the signiﬁcance
of these will not be known until the basic (composition
of matter) patents have expired and the existing patents
are ‘tested’ by generic companies entering the market.
For full cost analyses, other factors would need to be
included, such as any additional treatments adminis-
tered alongside these medicines, the cost of diagnostics,
and national health ﬁnancing mechanisms.
The TKIs surveyed are effective treatments that can be
taken orally, are easy to transport and store, and seldom
require an advanced care unit. Following lessons learnt
from HIV, affordable cancer medication could offer an
opportunity to rapidly scale up the treatment in
resource-poor settings if combined with infrastructure
development and health professional training. In coun-
tries where they are under patent protection, cancer
medicines at these target prices are likely to become
available only after patent expiry. Alternatively, central
patents could be invalidated, or compulsory licenses
could be issued before patent expiry, as was the case for
sorafenib and imatinib in India (see online supplemen-
tary appendix 2). In countries where the medicines are
not under patent protection, large buyers, such as gov-
ernments, NGOs and international agencies should
encourage the achievement of prices at the levels of our
estimates by ensuring that there is effective competition.
One option for pharmaceutical companies wishing to
increase access to their product without compromising
intellectual property rights could be to issue voluntary
licenses, such as those for HIV medicines issued to the
Medicines Patent Pool.28 Our estimates can also inform
tenders for medicines and negotiations with current
Hill A, et al. BMJ Open 2016;6:e009586. doi:10.1136/bmjopen-2015-009586 7
Open Access
group.bmj.com on February 4, 2016 - Published by http://bmjopen.bmj.com/Downloaded from 
manufacturers. This may be especially relevant to set-
tings where it is not feasible to offer widespread surgical
treatment, radiotherapy or traditional chemotherapy.
International agencies are investigating options for treat-
ment scale-up. Imatinib was recently included in the
WHO Essential Medicines List;9 the potential for low
prices demonstrated here could allow more cancer med-
icines to follow. As the medicines surveyed are approach-
ing patent expiry (table 2), generic manufacturers can
already begin preparing to launch generic versions, and
national and international purchasers can prepare for
scaling up of cancer treatment. The price-lowering
effects of generic competition have been demonstrated
in antiretrovirals for HIV,20 where price reductions in
excess of 95% have allowed massive increases in the pro-
portion of infected people that are on treatment.
In many cases, decisions on drug indications, their scope
and treatment lengths, are based partially on their price. If
generic versions are made available at these target prices,
this may allow re-evaluation of indication scope, greater dur-
ation of treatment, and even combination of TKIs (eg, erlo-
tinib and lapatinib are currently in trials for combination
treatments).29 Other drugs in the same class as those ana-
lysed, such as ibrutinib and vemurafenib, are under patent
protection and currently priced at a level that is unafford-
able in many settings. Similar analyses may be done for
these medicines and other novel cancer treatments.
CONCLUSIONS
Pharmaceutical companies need to recoup investments
in research and development to remain ﬁnancially viable.
However, the TKIs analysed have already accumulated bil-
lions of dollars in sales, and after patent protection has
lapsed, there is no justiﬁcation for prices to remain sig-
niﬁcantly above the target prices of production described
in this paper. In the case of sorafenib, the CEO of the ori-
ginator company, Bayer, has commented that the proﬁts
made from sorafenib in India do not affect their business
model.30 The current global prices of TKIs make these
treatments unaffordable and unavailable in developing
countries and some high-income countries. The ﬁndings
of this paper demonstrate that scaling up cancer treat-
ment using cheap, generic TKIs is feasible as soon as
patent protection is lost. In the interim, alternative
mechanisms can be used to reduce prices and allow
access to cancer treatments. These mechanisms include
using so-called ‘ﬂexibilities’ in the World Trade
Organization’s Agreement on Trade-Related Aspects of
Intellectual Property Rights (TRIPS) to allow generic
manufacture and/or importation, and the granting of
licenses by originator companies to generic manufac-
turers, for supply of the developing country market.
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